A phase II nonrandamized study with triple negative breast cancer patients is currently evaluating the temsirolimus, an intravenous mTOR inhibitor and a phase III randamized study with a neoadjuvant setting is currently evaluating everolimus in combination with antracyclines and taxanes [34]. This evidence concerns the gene MTOR and triple-negative breast carcinoma.